Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (465)	6/17/1999 9:54:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3158

Some important points....... >> the BTK index is heavy on the first tiers, the rest of the biotechs are relatively even cheaper than you indicate. << As everybody is sick of hearing me say over and over again....... the quality science companies in the lowest tier are as cheap as technology in the sector has ever been. It is ridiculous. The companies in the first tier that use their strong currencies (MLNM et al., but it again looks like AMGN just isn't poking in the correct corners) now are going to be Dow stocks within 20 years. >> This means, as you pointed out, that the window is definitely closing. << Geeeze, have management teams (GILD, VLTS and a few others excepted) been slow to react (not saying that the "reactions" to date were among the wisest of moves...... GILD was way too conservative, IMO, and VLTS is a study in process)!